Form 4: Immunovant's Chief Medical Officer, Michael Geffner, Reports Stock and Option Transactions

Michael Geffner, Chief Medical Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options.

Summary

• On April 1, 2025, Michael Geffner, the Chief Medical Officer of Immunovant, Inc., acquired 101,574 restricted stock units (RSUs) and 143,063 stock options.
• The RSUs were granted under the company's 2019 Equity Incentive Plan and represent the right to receive one share of common stock per unit upon vesting.
• 25% of the RSUs will vest on April 1, 2026, with the remaining units vesting in equal quarterly installments over the following three years, contingent upon continuous service.
• The stock options, with an exercise price of $15.20, also vest with 25% on April 1, 2026, and the remainder in 36 equal monthly installments over three years, subject to continuous service.
• Following these transactions, Geffner directly owns 233,888 shares of Immunovant common stock and 143,063 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity suggests confidence in the executive and the company's future, but it's a routine transaction.

Positives

• The grant of RSUs and stock options to the Chief Medical Officer aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the equity grants suggest an expectation of continued service and contribution from the Chief Medical Officer.

Industry Context

Equity grants are a common practice in the biotechnology industry to incentivize and retain key executives. The vesting schedules are designed to align management's interests with long-term shareholder value.

Comparison to Industry Standards

• Equity compensation packages for Chief Medical Officers in biotech companies typically include a mix of stock options and restricted stock units.
• Vesting schedules are generally structured over a three-to-four-year period to encourage long-term commitment.
• The specific amounts and terms of the grants would be benchmarked against peer companies of similar size and stage of development.

Stakeholder Impact

• The equity grants align the interests of the Chief Medical Officer with those of the shareholders.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Immunovant, IMVT, Michael Geffner, Chief Medical Officer, Form 4, Stock Options, Restricted Stock Units, Equity Incentive Plan, Beneficial Ownership, Vesting